Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
4
CANADA:2
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Phase 3
Completed
- Conditions
- Breast NeoplasmsEarly-stage Breast CancerBreast CancerHER2-positive Breast CancerStage II Breast CancerStage IIIA Breast Cancer
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Tanvex BioPharma USA, Inc.
- Target Recruit Count
- 338
- Registration Number
- NCT04109391
- Locations
- 🇧🇾
Tanvex Investigational Site 1003E, Gomel, Belarus
🇧🇾Tanvex Investigational Site 1006E, Grodno, Belarus
🇧🇾Tanvex Investigational Site 1008E, Lesnoy, Belarus
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Phase 3
Completed
- Conditions
- Stage II Breast CancerStage IIIA Breast CancerBreast CancerBreast NeoplasmsHER2-positive Breast Cancer
- Interventions
- Biological: Herceptin®Biological: TX05 (trastuzumab)
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Tanvex BioPharma USA, Inc.
- Target Recruit Count
- 809
- Registration Number
- NCT03556358
- Locations
- 🇧🇾
Tanvex Investigational Site 1008, Lesnoy, Minsk Region, Belarus
🇧🇾Tanvex Investigational Site 1007, Babruysk, Mogilev Region, Belarus
🇧🇾Tanvex Investigational Site 1003, Gomel, Belarus
News
No news found